These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8886913)

  • 41. Prostate specific antigen density of the transition zone for early detection of prostate cancer.
    Djavan B; Zlotta AR; Byttebier G; Shariat S; Omar M; Schulman CC; Marberger M
    J Urol; 1998 Aug; 160(2):411-8; discussion 418-9. PubMed ID: 9679889
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Evaluation of prostate specific antigen (PSA) adjusted to transition zone in prostatic cancer detection].
    Jara Rascón J; Subirá Rios D; Lledó Garcia E; Martínez Salamanca JI; Moncada Iribarren I; Hernández Fernández C
    Actas Urol Esp; 2005 May; 29(5):485-92. PubMed ID: 16013794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prostate-specific antigen density: correlation with histological diagnosis of prostate cancer, benign prostatic hyperplasia and prostatitis.
    van Iersel MP; Witjes WP; de la Rosette JJ; Oosterhof GO
    Br J Urol; 1995 Jul; 76(1):47-53. PubMed ID: 7544204
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The usefulness of prostate-specific antigen (PSA) density in patients with intermediate serum PSA level in a country with low incidence of prostate cancer.
    Yu HJ; Lai MK
    Urology; 1998 May; 51(5A Suppl):125-30. PubMed ID: 9610567
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
    Presti JC; Hovey R; Carroll PR; Shinohara K
    J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
    Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
    Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.
    Djavan B; Zlotta A; Kratzik C; Remzi M; Seitz C; Schulman CC; Marberger M
    Urology; 1999 Sep; 54(3):517-22. PubMed ID: 10475364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml.
    Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y
    Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of serum level of prostate-specific antigen adjusted for the transition zone volume in early detection of prostate cancer.
    Ferreira MD; Koff WJ
    Int Braz J Urol; 2005; 31(2):137-45; discussion 146. PubMed ID: 15877833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Diagnostic algorithm based on a multivariate model to reduce the percentage of negative prostatic biopsies in patients with changed PSA or suspicious rectal palpation].
    Valer Algarabel J; Agüera Fernández L; Adot Zurbano JM; Virseda Chamorro M; Marcos Díez J; Gómez López A; Alpuente Román C
    Actas Urol Esp; 2000; 24(7):549-59. PubMed ID: 11011445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of prostate specific antigen density to predict clinically significant prostate cancer.
    Yusim I; Krenawi M; Mazor E; Novack V; Mabjeesh NJ
    Sci Rep; 2020 Nov; 10(1):20015. PubMed ID: 33203873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate-specific antigen density values among patients with symptomatic prostatic enlargement in Nigeria.
    Udeh EI; Nnabugwu II; Ozoemena FO; Ugwumba FO; Aderibigbe AS; Ohayi SR; Echetabu KN
    World J Surg Oncol; 2016 Jun; 14(1):174. PubMed ID: 27356753
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A higher PSA-density cut-off level in patients with intermediate PSA values for the early detection of prostate cancer.
    Mochtar CA; Rahardjo D; Umbas R
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():514-22. PubMed ID: 10895203
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Utility of prostate specific antigen (PSA) density in detecting prostate cancer in men showing gray zone serum PSA levels].
    Kihara T; Ito F; Kobayashi C; Ryoji O; Tokumoto T; Iguchi Y; Maeda Y; Onizuka S; Goya N; Nakazawa H; Toma H
    Hinyokika Kiyo; 1997 Jan; 43(1):13-8. PubMed ID: 9046415
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of PSA-related variables in improving positive ratio of biopsy of prostate cancer within serum PSA gray zone.
    Liu B; Pan TJ
    Urologia; 2014; 81(3):173-6. PubMed ID: 24557815
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Volume adjustment for intermediate prostate-specific antigen values in a screening population.
    Bangma CH; Grobbee DE; Schröder FH
    Eur J Cancer; 1995; 31A(1):12-4. PubMed ID: 7535074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy.
    Bare R; Hart L; McCullough DL
    Urology; 1994 Feb; 43(2):191-6. PubMed ID: 7509526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.